Notice of H1 2022 Results and Presentation

RNS Number : 4268X

HeiQ PLC

30 August 2022

 

30 August 2022

HeiQ Plc

("HeiQ" or "the Company")

Notice of H1 2022 Results and Presentation

HeiQ Plc (LSE: HEIQ), a Swiss IP innovator and established global brand in materials and textile innovation which operates in high-growth markets , is pleased to announce that its results for the six months ended 30 June 2022 ("H1 2022") will be published on Tuesday 13 September 2022.

H1 2022 Trading Update

HeiQ is pleased to report that the Company is expecting to report revenue of over US$30m for H1 2022, an increase of more than 17% compared to the six months ended 30 June 2021 ("H1 2021") (US$25.8m). This growth has been achieved despite the challenging macro-economic environment, including the  shutdown of key markets in China for over three months during the six-month period. The Company expects to report gross profit margins for H1 2022 of 46.7%, an improvement from the levels seen in the second half of the 2021 financial year (43.7%). Whilst the increased cost of raw materials placed pressure on margin during the period, pleasingly, the trend of margin improvement is continuing into the second half of this financial year ("H2 2022"), as the benefit of passed on price increases materialise and raw material costs start to stabilise.

HeiQ is pleased to report significant progress regarding the development of its potential blockbuster technologies:

· HeiQ successfully launched HeiQ AeoniQ, a high performance, climate positive, cellulose yarn designed as a sustainable substitute for the US$135 billion Polyester and Nylon market.

· Received investment from HUGO BOSS which provides an implied valuation of US$200 million for the platform.

· All contractual milestones with HUGO BOSS have been met, releasing US$9 million contractual payments and the pilot commercialisation plant has successfully commenced.

· Tangible progress has also been achieved for its other potential blockbuster technologies, HeiQ GrapheneX, with the validation of a solid state batteries prototype at double energy capacity, and HeiQ Synbio recognised in a peer reviewed publication by Europe's leading Hospital, Charité Berlin confirming the potential to reduce Hospital Acquired Infections

HeiQ has demonstrated a resilient trading performance during H1 2022 and the Directors remain optimistic that the Company will trade in-line with market guidance for the full financial year, although, like all companies, the Company is not immune from the impact of unforeseen global economic events and raw material spikes.

Details of briefing for equity analysts

Carlo Centonze, CEO, and Xaver Hangartner, CFO will host a briefing for analysts relating to its H1 2022 results for equity analysts at 09:30 a.m. BST on Tuesday 13 September 2022 . Any equity analysts wishing to attend or register should contact SEC Newgate UK at  [e-mail] where further details will be provided. 

Details of webinar for investors

The Company is also pleased to announce that Carlo Centonze and Xaver Hangartner will provide a live presentation relating to its H1 2022 results via the Investor Meet Company platform on Wednesday 14 September at 12:00 p.m. BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 a.m. the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet HeiQ Plc via:

https://www.investormeetcompany.com/heiq-plc/register-investor

Investors who have already registered and added to meet the Company will be automatically invited.

For further information, please contact:

HeiQ Plc Carlo Centonze (CEO)	[phone]
Cenkos Securities plc (Joint Broker) Stephen Keys / Callum Davidson	[phone]
SEC Newgate (Media Enquiries) Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton	[phone] HeiQ@s ecnewgate .co.uk

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. HeiQ has strong IP which is at the forefront of global technology in the $10 billion antimicrobial fabrics market, $24 billion textile chemicals market, the $50 billion probiotics market and the $150 billion man-made fibers market. It has also moved into the medical device, healthcare and hygiene coatings markets, to help make hospitals and healthcare environments more hygienic. HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance technologies in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands and it has a significant R&D pipeline containing over 50 projects. The Company has won multiple awards and gained a strong reputation for the ESG & sustainable downstream effect of its innovations. HeiQ is the only company to have won the Swiss Technology award twice. It has also won the Swiss Environmental award with an innovation that saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for partners, delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

 

END

 

 

MSCPFMITMTMTBPT